Int J Biol Sci 2013; 9(2):134-141. doi:10.7150/ijbs.4891
Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma
1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, P.R. China;
2. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, P.R. China;
3. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China;
4. Beijing Cellonis Biotechnologies Co., Ltd, 5 Kaituo Road, Zhongguancun Bio-Medicine Park, Beijing, 100085, P.R. China;
5. The Affiliated Bayi Brain hospital, the Military General Hospital of Beijing PLA, 100700, P.R. China;
6. The Department of Cell Biology, Peking University Health Science Center, Beijing,100091, P.R. China;
7. Peking University Stem Cell Research Center, Beijing, 100191, P.R. China.
# Common first author: Xiangli Cui, Zhiqin Xu.
Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q, Qin J, Hao L, Wang Z, Shen L, Lin S. Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma. Int J Biol Sci 2013; 9(2):134-141. doi:10.7150/ijbs.4891. Available from http://www.ijbs.com/v09p0134.htm
Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability and unpredictable clinical behavior. GBM is marked by an extremely poor prognosis with median overall survival of 12~14 months. In this study, we detected the CD137L-expressing cells and IL-17-expressing cells in tumor tissues resected from patients with GBM. Expression of CD137L and IL-17 were assessed by immunohistochemistry, and the prognostic value of CD137L and IL-17 expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. Immunohistochemical detection showed that positive cells of CD137L and IL-17 in glioblastoma tissue samples were 46.3% (19/ 41) and 73.2% (30/41) respectively. Expression of CD137L was not correlated with overall survival of GBM patients (P=0.594), while significantly longer survival rate was seen in patients with high expression of IL-17, compared to those with low expression of IL-17 (P=0.007). In addition, we also found that IL-17 expression was significantly correlated with Progression-free survival (PFS) (P=0.016) and death rate (P=0.01). Furthermore, multivariate Cox proportional hazard analyses revealed that IL-17 (P=0.018) and PFS (P=0.028) were independent factors affecting the overall survival probability. Kaplan-Meier analysis showed that PFS of high expression of IL-17 group were significantly longer (P=0.004) than low expression group with GBM. It is concluded that high levels of IL-17 expression in the tumor tissues may be a good prognostic marker for patients with GBM.
Keywords: CD137L, Interleukin-17, glioblastoma, overall survival.